PP
LCTX icon

Paloma Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Paloma Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-251,900
Closed -$219K – 2285
2020
Q2 		$219K Buy
+251,900
New +$222K ﹤0.01% 1642
2019
Q1 		– Sell
-23,200
Closed -$21K – 1815
2018
Q4 		$21K Sell
23,200
-2,289
-9% -$3.51K ﹤0.01% 1190
2018
Q3 		$52K Buy
+25,489
New +$53.5K ﹤0.01% 1471
2018
Q2 		– Sell
-14,630
Closed -$34K – 1951
2018
Q1 		$34K Hold
14,630
– – ﹤0.01% 1873
2017
Q4 		$28K Buy
+14,630
New +$31.9K ﹤0.01% 1828

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return